



5th Congress of the European Academy of Neurology

Oslo, Norway, June 29 - July 2, 2019

Teaching Course 1

Mitochondrial diseases for beginners (Level 1)

Mitochondrial diseases beyond the brain

Grainne Gorman

Newcastle upon Tyne, United Kingdom

Email: Grainne.Gorman@newcastle.ac.uk

Mitochondrial diseases **Beyond the brain**

Dr Grainne S Gorman
Wellcome Trust Centre for Mitochondrial Research
Newcastle University
UK



1

Conflict of Interest



In relation to this presentation and manuscript:


- the Author has no conflict of interest in relation to this manuscript.
- the Author received research support from Wellcome




2

Mitochondria and Mitochondrial Disease


3




4




5




6




7




8




9



10



11



12

Same Genotype: Different Phenotype

13



Ophthalmoplegia
Short stature
Deafness
Myopathy
Cardiac conduction defect [pacemaker]
Diabetes
Adrenal failure
Died age 7




Ophthalmoplegia
Short stature
Deafness
Myopathy
Cardiac conduction defect
Aged 44



Ophthalmoplegia
Aged 68

14

Leber's Hereditary Optic Neuropathy (LHON)



11778G>A, *MTND4*


15

Dystonia Phenotype



**Dystonia and Complex I Deficiency:
m.11778G>A**

16



- Maternally Inherited Diabetes and Deafness
- Chronic Progressive External Ophthalmoplegia
- Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like episodes
- Over half of symptomatic patients do not have a 'syndrome'

JNNP **The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation—implications for diagnosis and management**


Victoria Nesbitt, Robert D S Pitceathly, Doug M Turnbull, et al.

J Neurol Neurosurg Psychiatry 2013 84: 936-938 originally published online January 25, 2013
doi: 10.1136/jnnp-2012-303528

17

m.3243A>G *MTTL1*






18

Seizures and Stroke-like episodes

Healthy subject Patient (m.3243A>G)

welcome trust centre for Mitochondrial Research Newcastle University

19

m.3243A>G *MTTL1*

Only 10% of Newcastle Cohort recruits with the m.3243A>G have had stroke-like episodes

40% 96%

Monotard[®] HM
180 kOhm, 3Vdc
100% Relative Humidity
Equivalent for 1000h
100% Rel. Hum. 12Vdc
100% Rel. Hum. 12Vdc

20

Annals of NEUROLOGY An Official Journal of the American Neurological Association and the Child Neurology Society

AMERICAN NEUROLOGICAL ASSOCIATION

Review

Leigh syndrome: One disorder, more than 75 monogenic causes

Nicole J. Lake MSc, Alison G. Compton PhD, Shamima Rahman MD, PhD, David R. Thorburn PhD

First published: 27 October 2015 | <https://doi.org/10.1002/ana.24551> | Cited by: 96

Aetiology of Leigh Syndrome

Diagram illustrating the aetiology of Leigh Syndrome, showing various genetic mutations (e.g., PDZRN4, PDZRN1, PDZRN3, PDZRN2, PDZRN4) and their effects on the brain, including the brainstem and basal ganglia.

Leigh Syndrome

Symmetrical changes in basal ganglia and brainstem on MRI

21

Original Paper

Novel *MTND1* mutations cause isolated exercise intolerance, complex I deficiency and increased assembly factor expression

Guohua S. Gao^{1†}, Emma L. Skelley^{1†}, Hue-Tam Hong Do^{1,2}, Helen A.L. Tuppen³, Liam D. O'Connell⁴, Langyang He⁵, Angela Baker⁶, Gavin Fellous⁶, Jane Newson¹, Michael I. Yernool¹, Bryan Leiby⁷, Richard K. Peily⁸, Drag M. Stokich⁹, Robert McFarland⁸ and Robert W. Taylor⁸


¹Medical Unit Centre for Mitochondrial Research, Institute of Neurosciences, Newcastle University, Newcastle upon Tyne NE2 4BW, UK; ²Shanghai Institute of Cell and Tissue Biology, Chinese Academy of Sciences, Shanghai 200031, China; ³The James Cook 800, James Cook University, Cairns 4878, QLD, Australia; ⁴Department of Neurology, Southern General Hospital, Glasgow G21 4JF, UK; ⁵Department of Neurology, Southern General Hospital, Glasgow G21 4JF, UK; ⁶Department of Neurology, Southern General Hospital, Glasgow G21 4JF, UK; ⁷Department of Neurology, Southern General Hospital, Glasgow G21 4JF, UK; ⁸Department of Neurology, Southern General Hospital, Glasgow G21 4JF, UK; ⁹Department of Neurology, Southern General Hospital, Glasgow G21 4JF, UK

Dot plot showing the distribution of complex I activity for control and patient groups. The y-axis is labeled 'Complex I' and ranges from 0 to 20. The x-axis has two categories: 'CONTROL (n=10)' and 'PATIENT (n=10)'. The control group shows a higher median activity compared to the patient group.

Photograph of a patient's foot showing exercise intolerance.

22

Ptosis and CPEO



m.3243A>G



m.8344A>G



SLSD of mtDNA (KSS)



SLSD of mtDNA



POLG (AR)



PEO1 (AD)

23




CPEO Chronic Progressive Ophthalmoplegia


24



25




26



27




28




29

Clinical, histochemical and mtDNA abnormalities




A, Typical clinical features of a patient with mitochondrial PEO; the patient is asked to look left (i), right (ii), up, (iii) and down (iv). B, Sequential COX-SDH histochemistry of representative diagnostic muscle biopsies showing the presence of scattered COX-deficient fibres in patients with various disorders of adult-onset mtDNA maintenance abnormalities including (i) recessive (homozygous p.(Ala467Thr)) POLG mutations; (ii) a dominant, heterozygous p.(Gln458His) *C10ORF2* mutation; (iii) recessive p.(Arg186Gly) and p.(Thr218Ile)) RRM2B mutations; (iv) recessive p.(Asn288*) and p.(Lys558*) SPG7 mutations; (C) Southern blotting of muscle DNA showing a control (lane 1), a single, large-scale mtDNA deletion (lane 2) and the typical banding pattern observed with multiple mtDNA deletions (lanes 3 and 4); (D) Long-range PCR also indicating the presence of multiple mtDNA deletions (lane 3) alongside a control (lane 2) and size markers (lane 1).


30




31




32



33



34



35

Acute setting 74 yo

- Ptosis (marked)
- CPEO (mild)
- Bilateral facial weakness
- Dysarthria; bulbar weakness (mild)
- Proximal muscle weakness
- Diaphragmatic weakness
- Areflexia

- Arterial blood gas: Type II resp failure
 - CO₂:
 - pO₂:9.97
 - Nocturnal hypoventilation


- EMG/NCS:
 - SMAN
 - Mild myotonic features



36



37



38



39


Systems based approach: **case reports**

40


Endocrine and Diabetes

41


Short stature and low BMI




42



43



44



45

Mitochondrial disease and pregnancy

LOW BIRTH WEIGHT

1st trimester 2nd trimester 3rd trimester

Month: 1 2 3 4 5 6 7 8 9

Week: 4 8 11 15 20 25 30 35 40

High risk: Treatment and close monitoring

See this: www.prenatal.com

Get your baby's weight in kilograms, record it and plot it on the chart

46

Monitoring and Diabetes



welcome trust centre for
Mitochondrial Research



47

Cardiac and phenotypes

48

mtDNA	Cardiac Phenotype	nDNA
<p>m.1624C>T <i>MTTV</i> m.3243A>G <i>MTTL1</i> m.3260A>G <i>MTTL1</i> m.3303C>T <i>MTTL1</i> m.4269A>G <i>MTTI</i> m.4295A>G <i>MTTI</i> m.4300A>G <i>MTTI</i> m.4317A>G <i>MTTI</i> m.4320C>T <i>MTTI</i> m.8296A>G <i>MTTK</i> m.8344A>G <i>MTTK</i> m.8348A>G <i>MTTK</i> m.8529G>A <i>MTATP8</i> m.9997T>C <i>MTTG</i> m.12192G>A <i>MTTH</i> (Dilated) m.12297T>C <i>MTTL2</i> (Dilated) m.13513G>A <i>MTND5</i> m.15243G>A <i>MTCYB</i> m.15498G>A <i>MTCYB</i></p>	   	<p><i>SCO2</i> <i>COX15</i> <i>NDUFA2</i> <i>NDUF52</i> <i>NDUFV2</i> <i>SLC25A3</i> <i>SLC25A4</i> <i>ATPAF2</i></p> <p>TAZ1 (G4.5)</p> <p>FRDA (Frataxin)</p> <p>TK2</p> <p>AGK</p> <p>AARS2</p>
<p>Large single deletion (KSS)</p>		

49



50


Cardiac Involvement in the Mito Cohort (Newcastle)

- 18% (n=78)
- It is more prevalent in mtDNA mutations than common nuclear genes.

Genotype	Prevalence
m.3243A>G	25%
m.8344A>G	26%
Single deletion	15%
<i>POLG</i>	1/21
<i>PEO1</i>	0
<i>RRM2B</i>	1/15

51

Genotype-specific Cardiac Involvement



52

Cardiac and Cases 1

53



54

Sudden Adult Death Syndrome (SADS) in Asymptomatic m.3243A>G Carriers

30 year old male


- m.3243A>G mutation carrier (family screening)
- Fit & well, went to gym regularly
- Night out with friends and consumed some alcohol
- Found dead at home on the following day

33 year old female

- m.3243 mutation carrier (family screening)
- Full time teacher, referred for discussion of PGD. Mild LVH on cardiac screening
- Went out with friends, found dead at home next day

55

	Case 1	Case 2
Histochemistry		
Cardiac muscle	40-60% COX deficiency	15-20% COX deficiency
Skeletal muscle	20-30% COX deficiency	25%
Heteroplasmy level		
Cardiac muscle	91-95%	76-78%
Skeletal muscle	83-85%	90%
Brain tissue	90%	79-85%



Acknowledgement: Gavin Falkous & Nichola Lax

56

How common is SADS in m.3243A>G?

Review of historical cases and family pedigree = 6 possible cases; most recent suspected SADS case occurred in Dec 2014

Our estimated incidence of SADS in m.3243A>G = 2.4 per 1000 person-years

* Incidence of sudden unexpected death in population of ≤ 35 yo is 1 to 3.73 / 100,000


57

What should we do?




58

(a) Structural cardiac MRI



59

Predictors of Cardiomyopathy in m.3243A>G




Acknowledgement: J Grady

60

<http://research.ncl.ac.uk/mitoresearch/cardio/>

m.3243A>G Cardiomyopathy modelling



* Both blood and urine heteroplasmies are predictor for cardiomyopathy but blood is better.

Together with J Grady and G Gorman

61

Cardiac and Cases 2

62


Case : Back to basics

- 30 year old woman
- 6 years ago presented with intermittent episodes of
 - Occasional twitches when tired
 - 'off balance'
 - palpitations
- Familial screening: optic atrophy

63



64




65

Diagnoses:

- Myoclonus
- WPW- ablation therapy not required
- Developed lipomas on nap of neck and submandibular region (2007-2008)
- MERRF (8344A>G)


66




67



68




69



70

Distal weakness with respiratory insufficiency (MERRF)



(A) Clinical features include hair thinning, bilateral ptosis, and marked facial diplegia with prominent temporalis muscle wasting, jaw weakness and mild neck flexor and extension weakness. (B) Illustrates a severe mitochondrial histochemical defect, characterized by subsarcolemmal mitochondrial accumulation (ragged-red fibers) on the SDH reaction and in excess of 90% COX-deficient fibers following COX (C) and sequential COX-SDH (D) histochemistry. (E) Sequencing of the mitochondrial genome identified the well-characterised m.8344A > G MTK gene mutation (94% mutation load, muscle) but lower levels in blood and urine by quantitative pyrosequencing. (F) Maternal inheritance.

71

GIT and pseudo-obstruction

72


m.3243A>G *MTTL1*



Poor weight gain



Short stature



73

Bowel Dysmotility with m.3243A>G




PEG tube feeding




AXR may show bowel obstruction and faecal loading

74

Evolution of pseudo-obstruction



75



76



77

W
wellcome

Best Practice Guidelines

[Acute Stroke Post-Operative Care Guidelines](#) | [W & Gynaecology and Peri-Operative Guidelines](#)
[Hospital Pathology Guidelines](#) | [W & Gynaecology Guidelines](#)

<http://www.newcastle-mitochondria.com>

CLINICAL GUIDELINES
Home > Clinical Practice > Clinical Publications > Clinical Guidelines

[W & Gynaecology, Obstetrics and Perinatology Guidelines](#)
[W & Gynaecology, Vaccines Vaccine Guidelines](#)
[W & Gynaecology, Contraception Guidelines](#)
[W & Gynaecology, Perinatology Guidelines](#)

78

Pattern Recognition



79

Thank you



80